Tumor Growth

News Tumor Growth

• Clarifying the effect of stem cell therapy on cancer

  Injection of human stem cells into mice with tumors slowed down tumor growth, finds research published in BioMed Central's open access journal Stem Cell Research & Therapy. Human mesenchymal stem cells (MSC), isolated from bone marrow, caused changes in blood vessels supplying the tumor, and it is t more

• Protein improves efficacy of tumor-killing enzyme

  Scientists have devised a method for delivering tumor cell-killing enzymes in a way that protects the enzyme until it can do its work inside the cell. In their study in mBio®, researchers assembled microscopic protein packages that can deliver an enzyme called PEIII to the insides of cells. By attac more

• Researchers create cellular automation model to study complex tumor-host role in cancer

  Cancer remains a medical mystery – despite all of the research efforts devoted to understanding and controlling it. The most sought-after tumor model is one that would be able to formulate theoretical and computational tools to predict cancer progression and propose individual treatment strategies. more

Publications Tumor Growth

• Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs

  by Yi-Yu Lin, Hao-Wen Kao, Jia-Je Li, Jeng-Jong Hwang, Yun-Long Tseng, Wuu-Jyh Lin, Ming-Hsien Lin, Gann Ting, Hsin-Ell Wang Purpose PEGylated liposomes are important drug carriers that can passively target tumor by enhanced permeability and retention (EPR) effect in neoplasm lesions. This study more

• Common pathways to tumor rejection

  The control of tumor growth by the host's immunosurveillance is centered on the activation of interferon (IFN) pathways. In particular, direct study of tumors by various groups has uncovered an IFN‐γ–related signature whose presence is consistently associated with better prognosis, predisposition more

• Cell‐extrinsic effects of the tumor unfolded protein response on myeloid cells and T cells

  Tumor‐infiltrating myeloid cells, macrophages, and dendritic cells (DCs) are key regulators of tumor immunity and growth. The origin of tumor‐derived signals that instruct myeloid cells in the tumor microenvironment is only partially understood. The endoplasmic reticulum (ER) stress response, or u more

Market studies Tumor Growth

• Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS

  GBI Research's research, “Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS”, provides key data, information and analysis on the risk management and mitigation strategies, mandated by th more

• US FDA Approval of Afinitor Ends a Three Decade Long Wait for Pancreatic Neuroendocrine Tumor (PNET) Patients

  Introduction On May 5, 2011, the US Food and Drug Association (FDA) approved Afinitor (everolimus) for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease. It has become the first drug to be approved fo more

• Endothelin A Receptor Antagonist (atrasentan) Fails to Demonstrate an Advantage in the Treatment of Advanced Prostate Cancer

  Introduction This year another endothelin A receptor antagonist failed to demonstrate an advantage for advanced prostate cancer. With the failure of atrasentan in Phase III followed by the failure of two Phase III trials of zibotentan, there is only one trial left which is exploring an endothelin a more

Websites Tumor Growth